Skip to main content

ACR Best Abstracts - Day 4

The final day (day 4) of the ACR 2020 meeting saw a flurry of late-breaking abstracts and other novel studies that excited our faculty. Below are some of their choices for #ACRbest.

  1. 2020 #ACR20 RA guidelines were against steroid usage in RA. ESPOIR French cohort: 10 years of very low dose GC show increase events (death/CVD/fracture/severe ifn) even on low doses. HR increases every year. Cum GC dose-effect esp ifn, CVD.   Session 5M018 
  2. Tocilizumab NOT effective in preventing mechanical ventilation or death in moderately ill COVID-19 pts. Double-blind, Placebo, RCT (n=243)   Abstract #L07   
  3. Efficacy of TOFA vs PBO in AS. At week 16,  ASAS20 responders Tofa 56% v  PBO 29% ; ASAS40 Tofa 40% vs PBO 12%.  Abstract  #L11 
  4. Dr MacDonald presents FAST study: Febuxostat versus Allopurinol Streamlined Trial.  6128  gout patients. HR 0·89 [95% CI 0·75-1·06] for cardiovascular events in febuxostat vs allopurinol. Mortality 7.2% vs 8.6%. Reassuring rcardiovascular safety of febuxostat   Abstract  #L08
  5. Dr Cid presents phase 2 trial of anti-GM-CSF agent mavrilimumab in combination with steroids in GCA. 70 patients. Sustained remission at week 26 in 83.2% of mavrilimumab vs 49.9% of placebo p=0.0038.  #ACR20 Abstract #L06  
  6. Anakinra in #Stills disease - Double blind, placebo controlled RCT in Stills disease total 12pts, 6 placebo, 6 Rx grp.  All pts reached ACR70 at week 2 without fever and sustained it at 12 weeks. 5/6 reached ACR90   Abstract #1633
  7. Dr Baker reports on non-invasive vagal nerve stimulation to treat RA. 30 patients over 12 weeks. Mean DAS28-CRP decreased by 1.4. 53% achieved ACR20, 33% ACR50, 17% ACR70   Abstract #1995  
  8. Deucravacitinib TYK2i for PsA. Phase2b 16wk, Double-blind, Placebo, RCT w/ ACR20/50/70 response vs. PBO, HAQ-DI response, enthesitis resolution, MDA vs. PBO; No serious AE  Abstract #L03  
  9. Largest to date cohort study of pregnancies in women w/ ILD showed no maternal deaths suggesting that women w/ ILD may not need to avoid conception or terminate pregnancies, but pts w/ severe ILD were at higher risk for poor pregnancy outcomes.  Abstact #1446  
  10. No need to stop Tofa w/the flu?  Post hoc analysis 7964 Tofa pts over 14-15 flu seasons reported similar flu rates compared to ADA, MTX, PCB.  Tofa cont. in 70% pts; 28.8% stopped; mean days to resolution similar.  Abstract #L04 
  11. Do you have a problem with no-shows?  #ABS1584 discusses telemedicine and care access during COVID-19. Case Western observed a 0% cancellation rate,  <10% no-show rate, & 90% of scheduled telemed visits completed during COVID-19.
  12. Remission in early RA- Do you want the good news or the bad? 55% of ERA pts in Cdn CATCH cohort reached remission in >3000 pts followed but short lived victory. Half in remission 1 yr later & 40% at 2 yrs .  Abstract #1715


If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

The author has no conflicts of interest to disclose related to this subject